2797 Metixene Metixene is only found in individuals that have used or taken this drug. It is a anticholinergic used as an anti-parkinson drug. 4969-02-2 4167 C20H23NS 309.155120 < 25°C 173°C at 7.00E-02 mm Hg Soluble as HCl salt Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known. Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as metixene is considered to relate to competitive antagonism of acetylcholine at muscarinic receptors in the corpus striatum, which then restores the balance. Hepatic. Metabolism occurs via sulfoxydation and N-demethylation. No indication of carcinogenicity to humans (not listed by IARC). Used for the symptomatic treatment of parkinsonism. Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures. 2009-07-21T20:26:38Z 2026-03-31T17:57:08Z Metixene 51024 Metixene DB00340 true CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1 C20H23NS InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3 MJFJKKXQDNNUJF-UHFFFAOYSA-N 309.468 309.155120431 Exogenous Liquid 4.7 HMDB14484 4023 CHEM002174 DTXSID1047867 NS00009750 1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine